PMID- 21868333
OWN - NLM
STAT- MEDLINE
DCOM- 20130502
LR  - 20131121
IS  - 1673-4254 (Print)
IS  - 1673-4254 (Linking)
VI  - 31
IP  - 8
DP  - 2011 Aug
TI  - [Effect of losartan on renal expression of monocyte chemoattractant protein-1 and 
      transforming growth factor-beta(1) in rats after unilateral ureteral obstruction].
PG  - 1405-10
AB  - OBJECTIVE: To investigate the effect of losartan on the expression of monocyte 
      chemoattractant protein-1 (MCP1) and transforming growth factor-beta(1) (TGF-beta(1)) 
      in the kidney of rats with unilateral urethral obstruction (UUO) and evaluate 
      protective effect of losartan against reanal interstitial fibrosis. METHODS: Rat 
      models of UUO were treated with losartan at the routine dose, high dose, and very 
      high dose (50, 200, and 500 mg/kg daily, respectively), and saline was given to 
      UUO model rats and rats with sham operation. At 7, 14, and 21 days, the tail cuff 
      blood pressure (TCP), 24-h urine protein (Upro), serum Scr, BUN, K(+), percentage 
      of renal damage and renal interstitial fibrosis (%INT) were measured in the rats. 
      MCP1 protein in the renal tissues was detected using immunohistochemistry, and 
      MCP1 and TGF-beta(1) mRNA expressions were assayed using RT-PCR. RESULTS: As the UUO 
      prolonged, Upro, TCP, tubular damage, %INT, and MCP1 and TGF-beta(1) mRNA 
      expressions all increased significantly (P<0.05). High and very high doses of 
      losartan, compared with the routine dose, obviously reversed these changes. 
      CONCLUSION: High-dose losartan can effectively control blood pressure, reduce 
      renal damage and fibrosis, and inhibit MCP1 and TGF-beta(1) expression in rats with 
      UUO, and at a very high dose, losartan can more effectively reduce 24-h Upro than 
      the high-dose group. High and very high doses of losartan offer better protective 
      effect on the kidney in rats with UUO.
FAU - Huang, Yu-Yu
AU  - Huang YY
AD  - Department of Nephrology, Guangzhou First People's Hospital, Guangzhou, China. 
      huangyuyu2007@126.com
FAU - Xu, An-Ping
AU  - Xu AP
FAU - Zhou, Shan-Shan
AU  - Zhou SS
FAU - Fu, Jun-Zhou
AU  - Fu JZ
FAU - Du, Hong
AU  - Du H
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Nan Fang Yi Ke Da Xue Xue Bao
JT  - Nan fang yi ke da xue xue bao = Journal of Southern Medical University
JID - 101266132
RN  - 0 (Ccl2 protein, rat)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Tgfb1 protein, rat)
RN  - 0 (Transforming Growth Factor beta1)
RN  - JMS50MPO89 (Losartan)
SB  - IM
MH  - Animals
MH  - Chemokine CCL2/*metabolism
MH  - Fibrosis/etiology/prevention & control
MH  - Kidney/*metabolism/pathology
MH  - Losartan/*pharmacology
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Transforming Growth Factor beta1/*metabolism
MH  - Ureteral Obstruction/complications/*drug therapy
EDAT- 2011/08/27 06:00
MHDA- 2013/05/03 06:00
CRDT- 2011/08/27 06:00
PHST- 2011/08/27 06:00 [entrez]
PHST- 2011/08/27 06:00 [pubmed]
PHST- 2013/05/03 06:00 [medline]
PST - ppublish
SO  - Nan Fang Yi Ke Da Xue Xue Bao. 2011 Aug;31(8):1405-10.